Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients

<i>Background and Objectives</i>: Lung cancer is the second most common cancer in the world. Non-small-cell lung carcinoma (NSCLC) makes up 85% of all lung cancer cases and the majority of patients are diagnosed when the cancer is advanced. Over the years, many anticancer drugs have been...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ting Yoon Kwan, Ezharul Hoque Chowdhury
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	advanced non-small-cell lung carcinoma chemotherapy immunotherapy clinical outcomes objective response rate overall survival Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a7368c147106496abfb1c43ebaa63734
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7368c147106496abfb1c43ebaa63734
record_format	dspace
spelling	oai:doaj.org-article:a7368c147106496abfb1c43ebaa637342021-11-25T18:18:57ZClinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients10.3390/medicina571112521648-91441010-660Xhttps://doaj.org/article/a7368c147106496abfb1c43ebaa637342021-11-01T00:00:00Zhttps://www.mdpi.com/1648-9144/57/11/1252https://doaj.org/toc/1010-660Xhttps://doaj.org/toc/1648-9144<i>Background and Objectives</i>: Lung cancer is the second most common cancer in the world. Non-small-cell lung carcinoma (NSCLC) makes up 85% of all lung cancer cases and the majority of patients are diagnosed when the cancer is advanced. Over the years, many anticancer drugs have been designed and introduced into the market to treat patients with advanced NSCLC. This review aims to discuss the comparative therapeutic benefits of conventional chemotherapeutics and other drugs available for treating advanced NSCLC. <i>Materials and Methods:</i> A literature search for first-line treatment of advanced NSCLC was carried out on PubMed and Google Scholar. Objective response rate (ORR) and overall survival were chosen as target endpoints. <i>Results:</i> Monotherapy showed lower treatment endpoints compared to combination therapy. Different combinations of platinum-based doublets demonstrated similar efficacies in treating NSCLC. However, pemetrexed–platinum doublets showed significantly better treatment endpoint in patients with non-squamous NSCLC. Most studies showing the best complete response rate (CRR) utilized epidermal growth factor receptor (<i>EGFR)</i> tyrosine kinase inhibitors (<i>TKI</i>), while most studies producing the best overall survival included programmed death-1/programmed death-ligand 1 (<i>PD-1</i>/<i>PD-L1)</i> inhibitors in their treatment regimens. <i>Conclusions:</i> The findings of this review indicate that targeted therapy using specific inhibitors is now the most promising first-line anticancer treatment available in the market. However, chemotherapy is still effective in treating advanced NSCLC and is viable as a first-line treatment.Ting Yoon KwanEzharul Hoque ChowdhuryMDPI AGarticleadvanced non-small-cell lung carcinomachemotherapyimmunotherapyclinical outcomesobjective response rateoverall survivalMedicine (General)R5-920ENMedicina, Vol 57, Iss 1252, p 1252 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	advanced non-small-cell lung carcinoma chemotherapy immunotherapy clinical outcomes objective response rate overall survival Medicine (General) R5-920
spellingShingle	advanced non-small-cell lung carcinoma chemotherapy immunotherapy clinical outcomes objective response rate overall survival Medicine (General) R5-920 Ting Yoon Kwan Ezharul Hoque Chowdhury Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
description	<i>Background and Objectives</i>: Lung cancer is the second most common cancer in the world. Non-small-cell lung carcinoma (NSCLC) makes up 85% of all lung cancer cases and the majority of patients are diagnosed when the cancer is advanced. Over the years, many anticancer drugs have been designed and introduced into the market to treat patients with advanced NSCLC. This review aims to discuss the comparative therapeutic benefits of conventional chemotherapeutics and other drugs available for treating advanced NSCLC. <i>Materials and Methods:</i> A literature search for first-line treatment of advanced NSCLC was carried out on PubMed and Google Scholar. Objective response rate (ORR) and overall survival were chosen as target endpoints. <i>Results:</i> Monotherapy showed lower treatment endpoints compared to combination therapy. Different combinations of platinum-based doublets demonstrated similar efficacies in treating NSCLC. However, pemetrexed–platinum doublets showed significantly better treatment endpoint in patients with non-squamous NSCLC. Most studies showing the best complete response rate (CRR) utilized epidermal growth factor receptor (<i>EGFR)</i> tyrosine kinase inhibitors (<i>TKI</i>), while most studies producing the best overall survival included programmed death-1/programmed death-ligand 1 (<i>PD-1</i>/<i>PD-L1)</i> inhibitors in their treatment regimens. <i>Conclusions:</i> The findings of this review indicate that targeted therapy using specific inhibitors is now the most promising first-line anticancer treatment available in the market. However, chemotherapy is still effective in treating advanced NSCLC and is viable as a first-line treatment.
format	article
author	Ting Yoon Kwan Ezharul Hoque Chowdhury
author_facet	Ting Yoon Kwan Ezharul Hoque Chowdhury
author_sort	Ting Yoon Kwan
title	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
title_short	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
title_full	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
title_fullStr	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
title_full_unstemmed	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
title_sort	clinical outcomes of chemotherapeutic molecules as single and multiple agents in advanced non-small-cell lung carcinoma (nsclc) patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a7368c147106496abfb1c43ebaa63734
work_keys_str_mv	AT tingyoonkwan clinicaloutcomesofchemotherapeuticmoleculesassingleandmultipleagentsinadvancednonsmallcelllungcarcinomansclcpatients AT ezharulhoquechowdhury clinicaloutcomesofchemotherapeuticmoleculesassingleandmultipleagentsinadvancednonsmallcelllungcarcinomansclcpatients
_version_	1718411338314678272

Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients

Ejemplares similares